The IDH2 inhibitor Enasidenib (AG-221) and Ivosidenib are approved for relapsed/refractory AML in the presence of relevant mutations and ivosidenib was recently approved, in combination with hypomethylating agents, as first-line therapy for IDH1 mutant AML [Figure 1]. Here, IDH2 is linked to acute myeloid leukemia.